Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study

被引:20
作者
Ruggiero, Angelo [1 ,2 ]
Fabbrocicni, Gabriella [1 ]
Cacciapuoti, Sara [1 ]
Potestio, Luca [1 ]
Gallo, Lucia [1 ]
Megna, Matteo [1 ]
机构
[1] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Naples, Italy
[2] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Via Pansini 5, I-80131 Naples, Italy
来源
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY | 2023年 / 16卷
关键词
guselkumab; risankizumab; tildrakizumab; real-world practice; psoriasis; anti-IL-23; biologics; GUSELKUMAB; RISANKIZUMAB; PLACEBO;
D O I
10.2147/CCID.S402183
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Tildrakizumab, an anti-IL-23, showed promising efficacy and safety profiles in two randomized clinical-trials (reSURFACE-1 and reSURFACE-2), comparing tildrakizumab superiority to placebo and etanercept. Due to its recent availability in clinical-practice, real-life data are still limited.Objective: To assess the efficacy and safety of tildrakizumab in a real-world-practice in patients suffering from moderate-to-severe psoriasis.Methods: A 52-week observational retrospective study enrolled patients suffering from moderate-to-severe plaque-psoriasis, starting tildrakizumab treatment.Results: A total of 42 patients were included in the study. Mean PASI showed a significant reduction at each follow-up (p<0.001), reducing from 13.5 +/- 5.9 at baseline, 2.8 +/- 3.8 at week-28, resulting stable up to week-52. High rates of patients reached both PASI90 and PASI100 responses at both week 16 (PASI90: 52.4%, PASI100: 33.3%) and week 28 (PASI90: 76.1%, PASI100: 61.9%), maintaining these up to week 52 (PASI90: 73.8%, PASI100: 59.5%). The impact of treatment on patient's quality of life has been evaluated with DLQI, which showed a significant reduction during follow-ups.Conclusion: Our data confirm tildrakizumab as an effective and generally safe treatment for the management of moderate-to-severe psoriasis, with high rates of both PASI90 and PASI100 responses, and very few reported adverse events, up to 52 weeks of follow-up.
引用
收藏
页码:529 / 536
页数:8
相关论文
共 40 条
[1]   A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis [J].
Becher, Gabrielle ;
Conner, Sophia ;
Ingram, Jennifer A. ;
Stephen, Karen E. ;
McInnes, Alison C. ;
Heald, Adrian H. ;
Riley, Paul A. ;
Davies, Mark ;
Domenech, Arnau ;
Kasujee, Ismail .
DERMATOLOGY AND THERAPY, 2022, 12 (10) :2343-2354
[2]   Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial [J].
Blauvelt, Andrew ;
Papp, Kim A. ;
Griffiths, Christopher E. M. ;
Randazzo, Bruce ;
Wasfi, Yasmine ;
Shen, Yaung-Kaung ;
Li, Shu ;
Kimball, Alexa B. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (03) :405-417
[3]  
Brunasso AMG, 2022, J DRUGS DERMATOL, V21, P914, DOI [10.361349/JDD.6828, 10.36849/JDD.6828]
[4]  
Burlando Martina, 2021, Drugs Context, V10, DOI 10.7573/dic.2021-2-6
[5]   Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients [J].
Drerup, Katharina A. ;
Seemann, Claudia ;
Gerdes, Sascha ;
Mrowietz, Ulrich .
DERMATOLOGY, 2022, 238 (04) :615-619
[6]  
European Medicines Agency, 2018, ASS REP ILUM INT NON
[7]   Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis [J].
Galluzzo, Marco ;
Talamonti, Marina ;
Cioni, Arnaldo ;
Maffei, Virginia ;
Shumak, Ruslana Gaeta ;
Tofani, Lorenzo ;
Bianchi, Luca ;
Campione, Elena .
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (09)
[8]   Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study [J].
Gargiulo, Luigi ;
Ibba, Luciano ;
Pavia, Giulia ;
Vignoli, Carlo Alberto ;
Piscazzi, Francesco ;
Valenti, Mario ;
Sanna, Federica ;
Perugini, Chiara ;
Avagliano, Jessica ;
Costanzo, Antonio ;
Narcisi, Alessandra .
DERMATOLOGY AND THERAPY, 2022, 12 (10) :2309-2324
[9]   Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial [J].
Gerdes, Sascha ;
Braeu, Beate ;
Hoffmann, Matthias ;
Korge, Bernhard ;
Mortazawi, Dariusch ;
Wiemers, Franca ;
Wegner, Sven ;
Personke, Yvonne ;
Gomez, Mario ;
Sticherling, Michael .
JOURNAL OF DERMATOLOGY, 2021, 48 (12) :1854-1862
[10]   Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials [J].
Gordon, Kenneth B. ;
Strober, Bruce ;
Lebwohl, Mark ;
Augustin, Matthias ;
Blauvelt, Andrew ;
Poulin, Yves ;
Papp, Kim A. ;
Sofen, Howard ;
Puig, Lluis ;
Foley, Peter ;
Ohtsuki, Mamitaro ;
Flack, Mary ;
Geng, Ziqian ;
Gu, Yihua ;
Valdes, Joaquin M. ;
Thompson, Elizabeth H. Z. ;
Bachelez, Herve .
LANCET, 2018, 392 (10148) :650-661